Treatment efficacy CAPS, CIDI · adult participants (18 years and older) who have been exposed to any traumatic events, but who did not meet the diagnostic criteria for…
Propranolol showed no clear difference in treatment efficacy CAPS, CIDI compared with placebo (low certainty).
1 finding from 1 review
Treatment efficacy CAPS, SCID‐IV, PTSS‐10Q‐I · adult participants (18 years and older) who have been exposed to any traumatic events, but who did not meet the diagnostic criteria for…
Hydrocortisone probably leads to lower treatment efficacy CAPS, SCID‐IV, PTSS‐10Q‐I compared with placebo (moderate certainty).
1 finding from 1 review
Severity/intensity of MUPS (post‐treatment score on self report scales) Different self report and clinician‐rated scales (SOMS‐7, SCL‐90 Somatisation Score) · somatoform disorders in adults
1 finding from 1 review
Anxiety · somatoform disorders in adults
1 finding from 1 review
Endpoint score (HDRS or MADRS) · somatoform disorders in adults
1 finding from 1 review
Withdrawals due to adverse events · somatoform disorders in adults
New‐generation antidepressants showed no clear difference in adverse effects (drop‐outs due to adverse effects) compared with placebo (low certainty).
1 finding from 1 review
Treatment response (post‐treatment score on self report and clinician‐rated scales) · somatoform disorders in adults
It is very uncertain whether new‐generation antidepressants changes treatment response (post‐treatment score on self report and… compared with placebo (very low certainty).
1 finding from 1 review
Quality of life at post‐treatment Indexed by self‐report measures of quality of life or functional disability · somatoform disorders in adults
1 finding from 1 review
Severity/intensity of MUPS (post‐treatment score on self report scales) Different self report and clinician‐rated scales (SOMS‐7, SCL‐90 Somatisation Score) · somatoform disorders in adults
1 finding from 1 review
Acceptability · somatoform disorders in adults
Natural products showed no clear difference in acceptability (all‐cause drop‐outs4) compared with placebo (low certainty).
1 finding from 1 review
Anxiety · somatoform disorders in adults
1 finding from 1 review
Depression (post‐treatment score on self report and clinician‐rated scales) Different self report and clinician‐rated scales (HDRS, BDI) · somatoform disorders in adults
1 finding from 1 review
Adverse effects (drop‐outs due to adverse effects4) · somatoform disorders in adults
Natural products showed no clear difference in adverse effects (drop‐outs due to adverse effects4) compared with placebo (low certainty).
1 finding from 1 review
Acceptability · somatoform disorders in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment response (post‐treatment score on self report and clinician‐rated scales) · somatoform disorders in adults
It is very uncertain whether natural products changes treatment response (post‐treatment score on self report and… compared with placebo (very low certainty).
1 finding from 1 review
Quality of life at post‐treatment Indexed by self‐report measures of quality of life or functional disability · somatoform disorders in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severity/intensity of MUPS (post‐treatment score on self report scales) Different self report scales (VAS‐Pain, SCL‐90‐R Somatisation Subscore) · somatoform disorders in adults
1 finding from 1 review
Acceptability · somatoform disorders in adults
Tricyclic antidepressants showed no clear difference in acceptability (all‐cause drop‐outs4) compared with another medication (low certainty).
1 finding from 1 review
Anxiety · somatoform disorders in adults
1 finding from 1 review
Depression (post‐treatment score on self report and clinician‐rated scales) Different self report and clinician‐rated scales (HDRS, BDI) · somatoform disorders in adults
1 finding from 1 review